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The DETECT I trial is an impressive pragmatic, retrospective review of the records of more than 2,600
multicenter, prospective observational trial that seeks
to inform current practice regarding the optimal
workup of hematuria, which is a common and
expensive occurrence. This study adds important ev-
idence to the growing body of literature questioning
the usefulness of CTU in the workup of microscopic
hematuria as recommended by AUA guidelines
(reference 3 in article). Notably guidelines define
microscopic hematuria as more than 3 red blood cells
per high power field compared to a positive dipstick in
DETECT. The possibility of false-positive results
makes this cohort at lower risk than cohorts in which
microscopic hematuria is confirmed. However, the
incidence of UTUC in this study is in line with that of
other work. Of the 475 cases in which CTU as well as
ultrasound was done there was no case of UTUC. Apatients with asymptomatic microscopic hematuria
similarly showed no patient with UTUC.1
CTU exposes patients to additional costs, radiation
and contrast administration. The incremental cost to
detect 1 case of bladder cancer, kidney cancer or
UTUC by CT and cystoscopy has been estimated at
$6.5 million compared to about $54,000 for ultrasound
and cystoscopy (reference 20 in article). In appropriate
patients ultrasound can significantly decrease the
risks and costs of microscopic hematuria evaluation
with a minimal impact on sensitivity.Anobel Y. Odisho
Department of Urology
University of California, San Francisco
San Francisco, CaliforniaREFERENCE
1. Loo RK, Lieberman SF, Slezak JM et al: Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013;
88: 129.This study by Tan et al is a post hoc analysis of the initial evaluation of microscopic hematuria
3,556 patients enrolled in the DETECT I prospec-
tive multicenter observational study.1 Their goal
was to determine whether RBUS could replace
CTU for the investigation of patients with micro-
scopic hematuria. The authors found that RBUS
can safely replace CTU in patients with micro-
scopic hematuria but CTU should be done to
investigate gross hematuria.
The authors present a timely analysis which
adds to the current evidence base for the evalua-
tion of hematuria. Many urological associations
and medical groups already recommend RBUS forbut the level and grade of evidence of these rec-
ommendations is low (reference 2 in article). This
analysis from DETECT I will increase that level of
evidence and not only reassure surgeons who
currently practice that recommendation but it
should also challenge us to revise and unify
guidelines for the evaluation of these patients.
As the authors point out, in an ideal world every
patient would be investigated with the best test.
However, in the case of microscopic hematuria, for
which the incidence of UTUC is low and there is a
financial and health cost to CTU, these results justify
